Clinical Adoption Hinges on Workflow and Evidence
Leading medical device executives argue that regulatory clearance is insufficient for market success, citing workflow integration and robust clinical evidence as the primary determinants of whether a product is actually used in hospitals.
Medtronic executives emphasize that regulatory clearance does not guarantee commercial viability, noting that devices often fail to be adopted if they disrupt existing clinical routines. Melaine DiLuzio, VP of U.S. sales for enabling technologies at Medtronic, stated that the company embeds field and clinical teams directly in operating rooms to prevent products from becoming unused inventory. This approach addresses a critical gap between obtaining regulatory approval and achieving consistent clinical utilization.
The strategy relies on validating three specific criteria before launch. These include direct engagement with end-users, the provision of comprehensive clinical evidence, and financial justification for procurement. Executives from Medtronic, Edwards Lifesciences, and Plexāā identify these elements as the primary drivers of adoption, arguing that ignoring any of them leads to poor performance and wasted capital.
Workflow Integration Drives Adoption
DiLuzio argues that technology fails when it requires surgeons to abandon established workflows. She cited hundreds of examples where devices were rejected because they forced a complete change in operating room procedures. To mitigate this, Medtronic prioritizes understanding the daily routine of the OR, ensuring that new tools fit seamlessly into existing surgical practices rather than creating friction.
Plexāā, a breast cancer prehabilitation technology developer, adopts a similar user-centric approach by immersing its team in the patient experience. Gaele Lalahy, Chief Operating Officer, noted that the company gathers patients to identify unmet needs, ensuring the product aligns with real-world requirements. This includes having a patient champion on the senior executive team to guide decision-making and maintain focus on the end-user’s perspective.
Evidence Requirements for Physician Buy-In
Clinical evidence is essential to secure physician approval. Nina Goodheart, former SVP at Medtronic, described the SMART trial as a necessary step to provide doctors with data that justifies treating patients differently. The trial addressed specific clinical gaps, allowing physicians to confidently recommend the device based on robust proof of benefit rather than marketing claims alone.
Plexāā faced a similar hurdle, requiring a full randomized control trial to demonstrate the benefit of supraphysiological preconditioning on wound healing. Founder Dr. Saahil Mehta spent approximately seven years conducting this study in the U.K. This long-term investment in evidence was critical to establishing the scientific credibility needed to convince medical professionals of the device's efficacy.
Financial Justification and Patient Input
Financial approval is the second gate for adoption, requiring justification for both the physician and the healthcare system. Edwards Lifesciences engages patients to determine what resources they need, using this feedback to inform product development and value propositions. Sarah Huoh, Public Affairs VP, highlights that understanding patient needs helps build the case for cost-effectiveness and improved outcomes.
Biolinq Advanced Sensor Technologies leverages patient feedback to refine its glucose sensing devices for type 2 diabetes management. Rebecca Gottlieb, VP, explained that insights from patients with diabetes helped shape a unique user interface that provides clear range guidance. This direct input ensures the product addresses specific user frustrations, supporting both clinical utility and financial justification for its use.
